- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor Telaglenastat
- Arginase Inhibitor INCB001158
- Arginase Inhibitor
CB-280 - CD73 Inhibitor
CB-708 - IL4I1 Inhibitor
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Science
Publications and Presentations
Check out our publications and poster presentations.
March 2017
CB-839, a Selective Glutaminase Inhibitor, has Anti-Tumor Activity in Renal Cell Carcinoma and Synergizes with Cabozantinib and EverolimusKeystone Symposia on Tumor Metabolism
January 2017
December 2016
November 2016
Phase 1 Study of CB-839, a Small Molecule Inhibitor of Glutaminase, In Combination with Everolimus in Patients with Clear Cell and Papillary Renal Cell Carcinoma CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitorsNCI AACR EORTC – 2016
November 2016
Our Pipeline
We are focused on novel treatments for
cancer and other life-threatening diseases.